Jackie Fairley’s Melbourne-based biotech Starpharma fronted a small setback to its plans to launch a COVID-19-fighting nasal spray in the UK named Viraleze this week.
On Monday, Starpharma revealed the UK healthcare products regulator wrote to its UK distributor, LloydsPharmacy, to question the promotional claims made around Viraleze’s effectiveness in fighting COVID-19.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
